NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

$172.18

-0.48 (-0.28 %)

(As of 07/28/2021 12:00 AM ET)

Add

Compare

Today's Range

$172.08

▼

$173.38

50-Day Range

$161.98

▼

$172.66

52-Week Range

$133.65

▼

$173.65

Volume5.55 million shs

Average Volume7.51 million shs

Market Capitalization$453.42 billion

P/E Ratio25.89

Dividend Yield2.46%

Beta0.71

30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

US extends expiration dates on J&J COVID vaccine to 6 months
July 28, 2021 | marketbeat.com

South Africa's virus cases decline, liquor sales allowed
July 26, 2021 | marketbeat.com

Some French health workers resent, resist mandatory vaccines
July 26, 2021 | marketbeat.com

The Latest: States scale back virus reports despite surges
July 24, 2021 | marketbeat.com

The Latest: Tanzania gets 1 million J&J vaccines from U.S.
July 24, 2021 | marketbeat.com

The Latest: Oklahoma new virus cases top 1,000 for third day
July 23, 2021 | marketbeat.com

The Latest: US ships 22M vaccine doses to other countries
July 23, 2021 | marketbeat.com

The Latest: WH: US to buy 200M more doses of Pfizer vaccine
July 23, 2021 | marketbeat.com

The Latest: AP poll: Most unvaccinated unlikely to get shots
July 23, 2021 | marketbeat.com

The Latest: Australia state declares emergency over COVID-19
July 22, 2021 | marketbeat.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:JNJ
Previous Symbol
CUSIP47816010
CIK200406
Webwww.jnj.com
Phone732-524-0400
Employees134,500
Year Founded1886

Sales & Book Value

Annual Sales$82.58 billion
Price / Sales5.49
Cash Flow$10.91 per share
Price / Cash Flow15.78
Book Value$24.04 per share
Price / Book7.16

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares2,633,396,000
Market Cap$453.42 billion
Next Earnings Date10/12/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

2.55 out of 5 stars

Medical Sector

24th out of 2,210 stocks

Pharmaceutical Preparations Industry

14th out of 867 stocks

2.4 Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $190.38, Johnson & Johnson has a forecasted upside of 10.6% from its current price of $172.18.
Amount of Analyst Coverage
Johnson & Johnson has only been the subject of 3 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Johnson & Johnson has received 1,026 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Johnson & Johnson has received 525 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Johnson & Johnson has received 66.15% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote “Outperform” if you believe JNJ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 2.46%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 59 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 52.80%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.21% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.30% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
66.60% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 6.74% in the coming year, from $9.64 to $10.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 25.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.47.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 25.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 39.61.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 2.72. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

Is Johnson & Johnson a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Johnson & Johnson stock.
View analyst ratings for Johnson & Johnson or view top-rated stocks.

What stocks does MarketBeat like better than Johnson & Johnson?

Wall Street analysts have given Johnson & Johnson a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Johnson & Johnson wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, October 12th 2021.
View our earnings forecast for Johnson & Johnson.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Tuesday, July, 20th. The company reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.29 by $0.19. The business earned $23.31 billion during the quarter, compared to analyst estimates of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a trailing twelve-month return on equity of 37.78%. Johnson & Johnson's quarterly revenue was up 27.1% on a year-over-year basis. During the same period last year, the business posted $1.67 EPS.
View Johnson & Johnson's earnings history.

How has Johnson & Johnson's stock been impacted by Coronavirus (COVID-19)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JNJ shares have increased by 30.6% and is now trading at $172.18.
View which stocks have been most impacted by COVID-19.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Monday, July 19th. Stockholders of record on Tuesday, August 24th will be paid a dividend of $1.06 per share on Tuesday, September 7th. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.46%. The ex-dividend date of this dividend is Monday, August 23rd.
View Johnson & Johnson's dividend history.

Is Johnson & Johnson a good dividend stock?

Johnson & Johnson pays an annual dividend of $4.24 per share and currently has a dividend yield of 2.46%. Johnson & Johnson has been increasing its dividend for 59 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Johnson & Johnson is 52.80%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.21% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.
View Johnson & Johnson's dividend history.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY 2021 earnings guidance on Wednesday, July, 28th. The company provided earnings per share guidance of $9.600-$9.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.520. The company issued revenue guidance of $93.80 billion-$94.60 billion, compared to the consensus revenue estimate of $91.30 billion.

What price target have analysts set for JNJ?

9 equities research analysts have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $175.00 to $200.00. On average, they expect Johnson & Johnson's share price to reach $190.38 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Johnson & Johnson or view top-rated stocks among Wall Street analysts.

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:

Mr. Alex Gorsky, Chairman & CEO (Age 61, Pay $5M)
Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 54, Pay $1.98M)
Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 59, Pay $3.36M)
Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 58, Pay $2.89M)
Ms. Jennifer L. Taubert, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 57, Pay $1.92M)
Mr. Robert J. Decker Jr., Controller & Chief Accounting Officer (Age 49)
Mr. James Swanson, Exec. VP & Global CIO
Mr. Christopher DelOrefice, VP of Investor Relations
Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 62)
Ms. Ashley Watson, Chief Compliance Officer (Age 52)

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson CEO Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among Johnson & Johnson's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Johnson & Johnson's key competitors?

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of JNJ's competitors.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), The Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), The Procter & Gamble (PG) and AbbVie (ABBV).

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Manning & Napier Group LLC (0.07%), Marathon Asset Management LLP (0.06%), DAVENPORT & Co LLC (0.05%), Welch & Forbes LLC (0.03%), Bristol John W & Co. Inc. NY (0.02%) and Oregon Public Employees Retirement Fund (0.02%). Company insiders that own Johnson & Johnson stock include Ashley Mcevoy, Hubert Joly, Kathryn E Wengel, Michael E Sneed and William D Perez.
View institutional ownership trends for Johnson & Johnson.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Cardinal Capital Management Inc., Veracity Capital LLC, State of Alaska Department of Revenue, Country Trust Bank, Heritage Wealth Advisors, TCW Group Inc., XR Securities LLC, and Compagnie Lombard Odier SCmA. Company insiders that have sold Johnson & Johnson company stock in the last year include Ashley Mcevoy, Kathryn E Wengel, and Michael E Sneed.
View insider buying and selling activity for Johnson & Johnson or view top insider-selling stocks.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was purchased by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Oregon Public Employees Retirement Fund, IFM Investors Pty Ltd, Brookstone Capital Management, TIAA FSB, Manning & Napier Group LLC, LaFleur & Godfrey LLC, and Tandem Investment Advisors Inc.. Company insiders that have bought Johnson & Johnson stock in the last two years include Hubert Joly, and William D Perez.
View insider buying and selling activity for Johnson & Johnson or or view top insider-buying stocks.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $172.18.

How much money does Johnson & Johnson make?

Johnson & Johnson has a market capitalization of $453.42 billion and generates $82.58 billion in revenue each year. The company earns $14.71 billion in net income (profit) each year or $8.03 on an earnings per share basis.

How many employees does Johnson & Johnson have?

Johnson & Johnson employs 134,500 workers across the globe.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiares of Johnson & Johnson: ALZA Corporation, Abott Medical Optics, Acclarent, Actelion Pharmaceuticals, Advanced Sterilization Products Services Inc., Alios BioPharma, Animas Corporation, Apsis, Apsis Germany GmbH, Aragon Pharmaceuticals, Auris Health, Beijing Dabao Cosmetics Co., Berna Rhein B.V., BioMedical Enterprises, Biosense Webster, Biosense Webster (Israel) Ltd., CNA Development GmbH, Centocor Research & Development, Ci:z Holdings, Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Finance Unlimited Company, Cilag Pharmaceuticals GmbH, Codman & Shurtleff, Coherex Medical, Conor MedSystems, Cordis Financing Corporation, Cordis LLC, Cordis de Mexico, Covagen AG, Crucell N.V., DePuy France, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mitek, DePuy Orthopaedics, DePuy Products, DePuy Spine, DePuy Synthes, DePuy Synthes Apollo Limited, DePuy Synthes Eos Limited, DePuy Synthes Gorgan Limited, DePuy Synthes Jason Limited, DePuy Synthes Leto S.A.R.L., DePuy Synthes Products, DePuy Synthes Sales, Diabetes Diagnostics, EES, Ethicon, Ethicon Endo-Surgery, Ethicon Endo-Surgery LLC, Ethicon Holding Sarl, Ethicon Ireland, Ethicon LLC, Ethicon PR Holdings, Ethicon US, Ethicon Women's Health & Urology Sarl, Ethnor del Istmo, FMS Future Medical System SA, GMED Healthcare BVBA, Global Investment Participation B.V., J&J Holdings (Nevada), J-C Health Care Ltd., J.C. General Services CVBA, JJC Acquisition Company B.V., JJHC, JNJ International Investment LLC, JOM Pharmaceutical Services, Janssen, Janssen Biologics (Ireland), Janssen Biologics B.V., Janssen Biotech, Janssen Cilag Farmaceutica S.A., Janssen Egypt, Janssen Global Services, Janssen Infectious Diseases-Diagnostics BVBA, Janssen Irish Finance Company UC, Janssen Korea Ltd., Janssen Oncology, Janssen Ortho LLC, Janssen Pharmaceutica NV, Janssen Pharmaceutical, Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceuticals, Janssen Products, Janssen R&D Ireland, Janssen Research & Development, Janssen Sciences Ireland UC, Janssen Scientific Affairs, Janssen Supply Group, Janssen Vaccines & Prevention B.V., Janssen Vaccines AG, Janssen Vaccines Corp., Janssen de Mexico, Janssen-Cilag, Janssen-Cilag A/S, Janssen-Cilag AB, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica, Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag Kft., Janssen-Cilag Limited, Janssen-Cilag Limited (UK), Janssen-Cilag Manufacturing, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Pty Ltd, Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag S.p.A., Janssen-Cilag de Mexico, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (China) Ltd., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines), Johnson & Johnson (Proprietary) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson AB, Johnson & Johnson AG, Johnson & Johnson Belgium Finance Company, Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson European Treasury Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Group Holdings GmbH, Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International Financial Services Company, Johnson & Johnson Japan Inc., Johnson & Johnson K.K., Johnson & Johnson Korea, Johnson & Johnson Korea Selling & Distribution Limited Liability Company, Johnson & Johnson LLC, Johnson & Johnson Limitada, Johnson & Johnson Limited, Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Limited, Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico, Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty. Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pty. Limited, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.p.A., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services, Johnson & Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, Johnson & Johnson Swiss Finance Company Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care, Johnson & Johnson Vision Care (Ireland), Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Mexico, Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export & Import LLC, Johnson & Johnson s.r.o., Johnson & Johnson s.r.o. (Slovakia), Latam International Investment Company, Latam Properties Holdings, LifeScan, LifeScan Products, LifeScan Scotland Limited, Lifescan (France), McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Nutritionals, McNeil Products Limited, McNeil Sweden AB, Medical Devices & Diagnostics Global Services, Medos International Sarl, Medos Sarl, Mentor B.V., Mentor Holding PP, Mentor Medical Systems B.V., Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Pharmaceuticals, NeoStrata Company Inc., NeuWave Medical, Novira Therapeutics, OBTECH Medical Sarl, OMJ Ireland, OMJ PR Holdings, Omrix Biopharmaceuticals Ltd., Ortho Biologics LLC, Ortho Biotech Holding LLC, Orthotaxy, PMC Holdings G.K., PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals, Penta Pty. Limited, Pulsar Vascular, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Shanghai Johnson & Johnson Pharmaceuticals, Spectrum Vision Limited Liability Company, SterilMed, Synthes, Synthes GmbH, Synthes Holding AG, Synthes Lux Finance S.àr.l., Synthes Luxembourg, Synthes Produktions GmbH, Synthes USA, Synthes USA Products, TARIS Biomedical, The Anspach Effort, Turnbuckle Investment Company, Vania Expansion, Verb Surgical, Vogue International, XO1, Xian-Janssen Pharmaceutical Ltd., and Zarbee's Naturals.

When was Johnson & Johnson founded?

Johnson & Johnson was founded in 1886.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

Where are Johnson & Johnson's headquarters?

Johnson & Johnson is headquartered at ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 7/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here